Ferkul, Sean
Agabani, Zena
Minami, Osamu
Bormann, Jill
Le Foll, Bernard
Lobo, Leah
Hassan, Ahmed N.
Funding for this research was provided by:
The Innovation Fund of the Alternative Funding Plan for the Academic Health Sciences Centers of Ontario
Article History
Received: 20 February 2023
Accepted: 12 December 2023
First Online: 2 January 2024
Declarations
:
: Informed consent was obtained from all participants and this study was approved by CAMH’s research ethics board (018–2019). All methods were performed in accordance with the relevant guidelines and regulations.
: Not applicable.
: Dr. Bernard Le Foll received funding (grand awards and salary support) from Pfizer Inc. for investigator-initiated projects. He received funding from Indivior for a sponsored clinical trial. He has in-kind donations of cannabis products from Aurora Cannabis Enterprises Inc., nabixomols donation from GW Pharmaceuticals (funded by CIHR and NIH) and study medication donations from Pfizer Inc. and Bioprojet Pharma. Also, He obtained a coil for a Transcranial magnetic stimulation (TMS) study from Brainsway. Dr. Le Foll received industry funding (research grants) from Canopy Growth Corporation, Bioprojet Pharma, Alcohol Countermeasure Systems (ACS), Alkermes and Universal Ibogaine. He has participated in the National Advisory Board Meeting (Emerging Trends BUP-XR) for Indivior Canada and has been consultant for Shinogi. Mr. Sean Ferkul, Ms. Zena Agabani, Mr. Osamu Minami, Dr. Jill Bormann, Ms. Leah Lobo, and Dr. Ahmed N. Hassan have no competing interests to declare.